Last reviewed · How we verify
Radioimmunotherapy
Radioimmunotherapy is a Small molecule drug developed by University Hospital Tuebingen. It is currently in Phase 1 development.
Radioimmunotherapy is a form of unsealed source radiotherapy that uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell. It has been studied in clinical trials for various conditions, including Follicular Lymphoma, Anal Canal Cancer, and Anal Squamous Cell Carcinoma, using treatments such as a combination of modalities and Iodine-131 Anti-B1 Antibody.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Radioimmunotherapy |
|---|---|
| Sponsor | University Hospital Tuebingen |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial (PHASE2)
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors (PHASE1, PHASE2)
- Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma (PHASE1)
- A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors (PHASE1, PHASE2)
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
- Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma (PHASE2)
- Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma (PHASE1)
- Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Radioimmunotherapy CI brief — competitive landscape report
- Radioimmunotherapy updates RSS · CI watch RSS
- University Hospital Tuebingen portfolio CI
Frequently asked questions about Radioimmunotherapy
What is Radioimmunotherapy?
Who makes Radioimmunotherapy?
What development phase is Radioimmunotherapy in?
Related
- Manufacturer: University Hospital Tuebingen — full pipeline
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing